Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMP-01 in Social Anxiety Disorder
NCT06693609Phase 2Completed
- Sponsor
- atai Life Sciences
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Social Anxiety Disorder (SAD) comparing EMP-01 with EMP-01 Placebo (2 arms). Primary endpoints: Adverse Events at Day 43, Clinically Significant Abnormalities in Safety Parameters at Day 57 and 1 more. Started May 2025; status: completed.
02
Drugs
R-MDMA
03
Conditions
Social Anxiety Disorder (SAD)
Beyond the preview
Go deeper on NCT06693609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693609.